Acute Myelogenous Leukemia Treatment Information
Acute myelogenous leukemia (AML) is a hematological cancer in which the bone marrow produces abnormal myeloid cells. Myeloid cells are immature blood cells that – in a healthy individual – eventually develop into fully functioning red blood cells, platelets or non-lymphocytic white blood cells. In individuals with leukemia, however, this normal development process is interrupted, and the immature cells continue to divide longer than they should. This typically leads to a buildup of abnormal myeloid cells in the bloodstream.
Acute myelogenous leukemia is known by several other names, including:
- Acute myeloid leukemia
- Acute granulocytic leukemia
- Acute non-lymphocytic leukemia
At Moffitt Cancer Center, our Malignant Hematology Program provides comprehensive, individualized treatment for a range of blood and bone marrow cancers, including AML and other types of leukemia. We work consistently throughout each phase of a patient’s diagnosis, treatment and recovery to obtain the best possible outcomes – not only in terms of survival, but also quality of life.
Our Malignant Hematology Program goes above and beyond – starting with the very first consultation – to give each patient the best possible chance of achieving remission. Our multispecialty tumor board collaboratively considers a number of patient-specific factors to determine the most appropriate approach to initial treatment, otherwise known as induction therapy. Our recommendations to help a patient achieve AML remission might include chemotherapy, radiation therapy or targeted therapy.
Acute myelogenous leukemia often requires long-term (consolidation) therapy to maintain positive outcomes. Bone marrow transplantation, secondary chemotherapy and other options may be suggested to help a patient achieve the best possible outcome and quality of life. And, to offer our patients an even broader selection of treatment options, we host a number of clinical trials, which present invaluable opportunities to access the newest AML treatments before they are available in other settings.
Anyone who has been diagnosed with – or is experiencing symptoms of – acute myelogenous leukemia can meet with a Moffitt oncologist with or without a physician’s referral. To schedule an appointment with our Malignant Hematology Program, call 1-888-663-3488 or submit a new patient registration form online.